Allergan: Q2 results above estimates.
(CercleFinance.com) - Unveiled on Thursday before Wall Street opened, Allergan's Q2 accounts were marked by a substantial year-on-year increase in its loss per share.
Indeed, the loss per share rose from 1.25 dollar to 2.35 dollars.
However, on an adjusted basis, the US pharmaceutical group reported EPS of 4.02 dollars, 10 cents above the consensus.
Meanwhile, revenues rose from 3.685 billion dollars to 4.007 billion dollars, also above the consensus of 3.95 billion dollars.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Indeed, the loss per share rose from 1.25 dollar to 2.35 dollars.
However, on an adjusted basis, the US pharmaceutical group reported EPS of 4.02 dollars, 10 cents above the consensus.
Meanwhile, revenues rose from 3.685 billion dollars to 4.007 billion dollars, also above the consensus of 3.95 billion dollars.
Copyright (c) 2017 CercleFinance.com. All rights reserved.